Screener
Amneal Pharmaceuticals, Inc. AMRX Affordable Medicines — In-licensing and upfront milestones
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept amrx:InLicensingAndUpfrontMilestones.
The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001723128-26-000031
| Line item | Three Months Ended June 30, 2026 / Affordable Medicines | Three Months Ended June 30, 2026 / Specialty | Three Months Ended June 30, 2025 / Affordable Medicines | Three Months Ended June 30, 2025 / Specialty |
|---|---|---|---|---|
| Employee compensation and benefits | $12,016 | $1,326 | $14,693 | $1,279 |
| Materials and supplies | 8,796 | 1,022 | 8,108 | 450 |
| Product development and studies (1) | (89) | 2,615 | 756 | 2,371 |
| In-licensing and upfront milestones | 3,500 | — | 6,350 | — |
| Facilities costs | 1,479 | 30 | 1,793 | 735 |
| Regulatory fees | 1,334 | — | 2,932 | — |
| Other (2) | 5,987 | 1,001 | 7,267 | 1,230 |
| Total | $33,023 | $5,994 | $41,899 | $6,065 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Amneal Pharmaceuticals, Inc.'s affordable medicines — in-licensing and upfront milestones?
- Amneal Pharmaceuticals, Inc. (AMRX) reported affordable medicines — in-licensing and upfront milestones of $3.5M in Q2 2026.
- What does affordable medicines — in-licensing and upfront milestones mean?
- This metric represents the capital expenditure and contractual obligations associated with acquiring rights to pharmaceutical products or technologies through external licensing agreements. It reflects the strategic investment in expanding the product pipeline by securing third-party intellectual property before commercialization. Monitoring these costs provides insight into the company's reliance on external innovation versus internal R&D to sustain its portfolio of affordable generic and specialty medicines.
Ask your AI about Amneal Pharmaceuticals, Inc.'s affordable medicines — in-licensing and upfront milestones.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude